Last reviewed · How we verify
Fluzone Quadrivalent Influenza Vaccine
Fluzone Quadrivalent stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection.
Fluzone Quadrivalent stimulates the immune system to produce antibodies against four strains of influenza virus, providing protection against seasonal flu infection. Used for Seasonal influenza prevention in persons 6 months of age and older.
At a glance
| Generic name | Fluzone Quadrivalent Influenza Vaccine |
|---|---|
| Also known as | Fluzone® Quadrivalent Influenza Vaccine |
| Sponsor | Sanofi Pasteur, a Sanofi Company |
| Drug class | inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
The vaccine contains inactivated (killed) influenza virus particles representing four circulating strains (two A subtypes and two B lineages). When administered, it triggers both humoral and cellular immune responses, leading to the production of strain-specific antibodies and memory B cells. This immune priming allows the body to rapidly recognize and neutralize the corresponding live virus if exposure occurs, reducing infection risk and disease severity.
Approved indications
- Seasonal influenza prevention in persons 6 months of age and older
Common side effects
- Injection site soreness, redness, or swelling
- Fever
- Myalgia (muscle aches)
- Fatigue or malaise
- Headache
Key clinical trials
- Opioid, HIV and Immune System (PHASE4)
- BPL-1357 Against H1N1 Influenza Virus Challenge (PHASE2)
- Phase 3 Study to Evaluate the Immunogenicity and Safety of Inactived Split Influenza Vaccine in Healthy Korea Infants (PHASE3)
- Influenza Vaccination Strategy for Patients With Hematologic Malignancy (PHASE3)
- A Study to Evaluate the Safety and Immunogenicity of Two Doses of DCVC H1 HA mRNA-LNP in Healthy Adults (PHASE1)
- A Study To Learn About The Study Vaccine (Called Self-Amplifying Ribonucleic Acid (RNA)) For The Prevention of Influenza (PHASE1)
- A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age (PHASE3)
- A Study of Modified mRNA Vaccines in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: